Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phase I Study of Random Healthy Donor–Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors
Yaewon Yang, Okjae Lim, Tae Min Kim, et al.
Cancer Immunology Research (2016) Vol. 4, Iss. 3, pp. 215-224
Open Access | Times Cited: 133

Showing 1-25 of 133 citing articles:

The Tumor Microenvironment Innately Modulates Cancer Progression
Dominique C. Hinshaw, Lalita A. Shevde
Cancer Research (2019) Vol. 79, Iss. 18, pp. 4557-4566
Open Access | Times Cited: 2522
Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity
Ye Li, David Hermanson, Branden S. Moriarity, et al.
Cell stem cell (2018) Vol. 23, Iss. 2, pp. 181-192.e5
Open Access | Times Cited: 784
NK cell-based cancer immunotherapy: from basic biology to clinical development
Sizhe Liu, Vasiliy Galat, Yekaterina Galat, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 488
MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy
Annelisa M. Cornel, Iris Mimpen, Stefan Nierkens
Cancers (2020) Vol. 12, Iss. 7, pp. 1760-1760
Open Access | Times Cited: 323
Phase 1 clinical trial using mbIL21 ex vivo–expanded donor-derived NK cells after haploidentical transplantation
Stefan O. Ciurea, Jolie Schafer, Roland L. Bassett, et al.
Blood (2017) Vol. 130, Iss. 16, pp. 1857-1868
Open Access | Times Cited: 300
NK cell-based immunotherapy for cancer
Fang Fang, Weihua Xiao, Zhigang Tian
Seminars in Immunology (2017) Vol. 31, pp. 37-54
Closed Access | Times Cited: 277
Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients
Lin Xiao, Dongzhi Cen, Haining Gan, et al.
Molecular Therapy (2019) Vol. 27, Iss. 6, pp. 1114-1125
Open Access | Times Cited: 226
The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments
John P. Veluchamy, Nina Kok, Hans van Vliet, et al.
Frontiers in Immunology (2017) Vol. 8
Open Access | Times Cited: 178
Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy
Kyle B. Lupo, Sandro Matosevic
Cancers (2019) Vol. 11, Iss. 6, pp. 769-769
Open Access | Times Cited: 167
Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors
Gaurav Nayyar, Yaya Chu, Mitchell S. Cairo
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 146
CAR-NK cells for cancer immunotherapy: from bench to bedside
Leisheng Zhang, Meng Yuan, Xiaoming Feng, et al.
Biomarker Research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 128
Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
Erica L. Heipertz, Evan R. Zynda, Tor Espen Stav-Noraas, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 125
iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting
Benjamin Goldenson, Pooja Hor, Dan S. Kaufman
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 86
Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation
Markus Granzin, Juliane Wagner, Ulrike Köhl, et al.
Frontiers in Immunology (2017) Vol. 8
Open Access | Times Cited: 158
Ovarian Cancer Immunotherapy: Turning up the Heat
Eleonora Ghisoni, Martina Imbimbo, Stefan Zimmermann, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 12, pp. 2927-2927
Open Access | Times Cited: 142
Cellular therapy: Adoptive immunotherapy with expanded natural killer cells
Dean A. Lee
Immunological Reviews (2019) Vol. 290, Iss. 1, pp. 85-99
Closed Access | Times Cited: 111
Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with IgG1 antibody in patients with gastric or colorectal cancer
Takeshi Ishikawa, Tetsuya Okayama, Naoyuki Sakamoto, et al.
International Journal of Cancer (2018) Vol. 142, Iss. 12, pp. 2599-2609
Open Access | Times Cited: 98
Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells
Locke Uppendahl, Martin Felices, Laura E. Bendzick, et al.
Gynecologic Oncology (2019) Vol. 153, Iss. 1, pp. 149-157
Open Access | Times Cited: 95
Fabrication of BSA@AuNC-Based Nanostructures for Cell Fluoresce Imaging and Target Drug Delivery
Caifeng Ding, Yujuan Xu, Yanan Zhao, et al.
ACS Applied Materials & Interfaces (2018) Vol. 10, Iss. 10, pp. 8947-8954
Closed Access | Times Cited: 94
CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency
Feng Li, Yuqiao Sheng, Weizhou Hou, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 1, pp. e000131-e000131
Open Access | Times Cited: 86
Theranostic cells: emerging clinical applications of synthetic biology
Monica P. McNerney, Kailyn E. Doiron, Tai L. Ng, et al.
Nature Reviews Genetics (2021) Vol. 22, Iss. 11, pp. 730-746
Open Access | Times Cited: 82
NK cells to cure cancer
Clara Di Vito, Joanna Mikulak, Elisa Zaghi, et al.
Seminars in Immunology (2019) Vol. 41, pp. 101272-101272
Closed Access | Times Cited: 81
The role of natural killer cell in gastrointestinal cancer: killer or helper
Feixue Wang, Jennie Ka Ching Lau, Jun Yu
Oncogene (2020) Vol. 40, Iss. 4, pp. 717-730
Open Access | Times Cited: 73
Enhanced NK-92 Cytotoxicity by CRISPR Genome Engineering Using Cas9 Ribonucleoproteins
Rih‐Sheng Huang, Hsin-An Shih, Min‐Chi Lai, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 70
Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives
Keywan Mortezaee
Life Sciences (2021) Vol. 277, pp. 119627-119627
Closed Access | Times Cited: 60
Page 1 - Next Page

Scroll to top